Post Tue Sep 19, 2023 3:28 pm

2023-Pang et al-Pharmacol Res

"The combination of the HDC1 inhibitor SAHA and doxorubicin has synergic efficacy in triple negative breast cancer in vivo"
Yuheng Pang, Runze Shi, Liujia Chan, Yu Lu, Di Zhu, Tong Liu, Meisi Yan, Yuji Wang, Wenjing Wang
Pharmacol Res. 2023
https://doi.org/10.1016/j.phrs.2023.106926

- no dataset accession given